Tempus AI is trading 4.2% higher at $86.05, with no confirmed catalyst for the move. - No new company announcement on September 30 clearly explains the rise; the latest company-specific news is its September 28 FDA clearance for an AI tool to detect mitral regurgitation. - U.S. stock futures were slightly higher ahead of an inflation report, while supplied index readings showed gains under 0.5%. No confirmed trading-volume information is available.